Hidehito Horinouchi/X
Mar 29, 2025, 12:57
Hidehito Horinouchi: COCOON trial on preventing dermatologic adverse events in EGFR-mutant NSCLC
Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared a post on X:
“Now out.
COCOON: Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib.
Presented by Nicolas Girard.
AEs ≥G2: OR 0.19 (95% CI, 0.09–0.40)
NCT06120140.”
More posts featuring Hidehito Horinouchi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 21, 2025, 20:46
Apr 21, 2025, 20:30
Apr 21, 2025, 20:11
Apr 21, 2025, 19:55
Apr 21, 2025, 19:12
Apr 21, 2025, 18:19
Apr 21, 2025, 18:00
Apr 21, 2025, 17:40
Apr 21, 2025, 17:35
Apr 21, 2025, 17:29